Myeloid derived suppressor cells and their role in diseases

Current Medicinal Chemistry

Volumn 20, Issue 11, 2013, Pages 1437-1444

  Kong, Y Y ^a   Fuchsberger, M ^a   Xiang, S D ^a   Apostolopoulos, V ^b   Plebanski, M ^a  

^a MONASH UNIVERSITY   (Australia)

^b VA Consulting Services   (Australia)

Author keywords

Arginase 1; Chronic Inflammation; Dendritic Cells (Dcs); Granulocytes; Immune Response; Inducible Nitric Oxide Synthase (Inos); Monocytes; Myeloid derived suppressor cells (MDSCs); Reactive Oxygen Species (Ros); Suppression; Tumour Development

Indexed keywords

ARGINASE 1; CHEMOKINE RECEPTOR CCR2; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; PROTEIN S 100; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; CANCER CELL CULTURE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL INFILTRATION; DENDRITIC CELL; HUMAN; LEISHMANIASIS; MACROPHAGE; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SEPSIS; SUPPRESSOR CELL;

ANIMALS; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MYELOID PROGENITOR CELLS; NEOPLASMS;

EID: 84877949379     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320110006     Document Type: Article

References (90)

1. Dolcetti, L.; Peranzoni, E.; Ugel, S.; Marigo, I.; Fernandez Gomez, A.; Mesa, C.; Geilich, M.; Winkels, G.; Traggiai, E.; Casati, A.; Grassi, F.; Bronte, V., Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol, 2010, 40(1), 22-35.
2. Geissmann, F.; Jung, S.; Littman, D.R., Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity, 2003, 19(1), 71-82.
3. Rossner, S.; Voigtlander, C.; Wiethe, C.; Hanig, J.; Seifarth, C.; Lutz, M.B., Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol, 2005, 35(12), 3533-3544.
4. Angulo, I.; de las Heras, F.G.; Garcia-Bustos, J.F.; Gargallo, D.; Munoz-Fernandez, M.A.; Fresno, M., Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+) CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood, 2000, 95(1), 212-220.
5. Brys, L.; Beschin, A.; Raes, G.; Ghassabeh, G.H.; Noel, W.; Brandt, J.; Brombacher, F.; De Baetselier, P., Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol, 2005, 174(10), 6095-6104.
6. De Santo, C.; Salio, M.; Masri, S.H.; Lee, L.Y.; Dong, T.; Speak, A.O.; Porubsky, S.; Booth, S.; Veerapen, N.; Besra, G.S.; Grone, H.J.; Platt, F.M.; Zambon, M.; Cerundolo, V., Invariant NKT cells reduce the immunosuppressive activity of influenza A virusinduced myeloid-derived suppressor cells in mice and humans. J Clin Invest, 2008, 118(12), 4036-4048.
7. Delano, M.J.; Scumpia, P.O.; Weinstein, J.S.; Coco, D.; Nagaraj, S.; Kelly-Scumpia, K.M.; O'Malley, K.A.; Wynn, J.L.; Antonenko, S.; Al-Quran, S.Z.; Swan, R.; Chung, C.S.; Atkinson, M.A.; Ramphal, R.; Gabrilovich, D.I.; Reeves, W.H.; Ayala, A.; Phillips, J.; Laface, D.; Heyworth, P.G.; Clare-Salzler, M.; Moldawer, L.L., MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med, 2007, 204(6), 1463-1474.
8. Makarenkova, V.P.; Bansal, V.; Matta, B.M.; Perez, L.A.; Ochoa, J.B., CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol, 2006, 176(4), 2085-2094.
9. Haile, L.A.; von Wasielewski, R.; Gamrekelashvili, J.; Kruger, C.; Bachmann, O.; Westendorf, A.M.; Buer, J.; Liblau, R.; Manns, M.P.; Korangy, F.; Greten, T.F., Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology, 2008, 135(3), 871-881, 881 e871-875.
10. Pereira, W.F.; Ribeiro-Gomes, F.L.; Guillermo, L.V.; Vellozo, N.S.; Montalvao, F.; Dosreis, G.A.; Lopes, M.F., Myeloid-derived suppressor cells help protective immunity to Leishmania major infection despite suppressed T cell responses. J Leukoc Biol, 2011, 90(6), 1191-1197.
11. Solinas, G.; Germano, G.; Mantovani, A.; Allavena, P., Tumorassociated macrophages (TAM) as major players of the cancerrelated inflammation. J Leukoc Biol, 2009, 86(5), 1065-1073.
12. Bronte, V.; Serafini, P.; Mazzoni, A.; Segal, D.M.; Zanovello, P., L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol, 2003, 24(6), 302-306.
13. Rivoltini, L.; Carrabba, M.; Huber, V.; Castelli, C.; Novellino, L.; Dalerba, P.; Mortarini, R.; Arancia, G.; Anichini, A.; Fais, S.; Parmiani, G., Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev, 2002, 188, 97-113.
14. Zhao, F.; Obermann, S.; von Wasielewski, R.; Haile, L.; Manns, M.P.; Korangy, F.; Greten, T.F., Increase in frequency of myeloidderived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology, 2009, 128(1), 141-149.
15. Ilkovitch, D.; Lopez, D.M., The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res, 2009, 69(13), 5514-5521.
16. Kusmartsev, S.; Nefedova, Y.; Yoder, D.; Gabrilovich, D.I., Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol, 2004, 172(2), 989-999.
17. Youn, J.I.; Nagaraj, S.; Collazo, M.; Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol, 2008, 181(8), 5791-5802.
18. Huang, B.; Lei, Z.; Zhao, J.; Gong, W.; Liu, J.; Chen, Z.; Liu, Y.; Li, D.; Yuan, Y.; Zhang, G.M.; Feng, Z.H., CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer letters, 2007, 252(1), 86-92.
19. Movahedi, K.; Guilliams, M.; Van den Bossche, J.; Van den Bergh, R.; Gysemans, C.; Beschin, A.; De Baetselier, P.; Van Ginderachter, J.A., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood, 2008, 111(8), 4233-4244.
20. Gallina, G.; Dolcetti, L.; Serafini, P.; De Santo, C.; Marigo, I.; Colombo, M.P.; Basso, G.; Brombacher, F.; Borrello, I.; Zanovello, P.; Bicciato, S.; Bronte, V., Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest, 2006, 116(10), 2777-2790.
21. Huang, B.; Pan, P.Y.; Li, Q.; Sato, A.I.; Levy, D.E.; Bromberg, J.; Divino, C.M.; Chen, S.H., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res, 2006, 66(2), 1123-1131.
22. Serafini, P.; Borrello, I.; Bronte, V., Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol, 2006, 16(1), 53-65.
23. Lechner, M.G.; Megiel, C.; Russell, S.M.; Bingham, B.; Arger, N.; Woo, T.; Epstein, A.L., Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. Journal of translational medicine, 2011, 9, 90.
24. Brandau, S.; Trellakis, S.; Bruderek, K.; Schmaltz, D.; Steller, G.; Elian, M.; Suttmann, H.; Schenck, M.; Welling, J.; Zabel, P.; Lang, S., Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol, 2011, 89(2), 311-317.
25. Vuk-Pavlovic, S.; Bulur, P.A.; Lin, Y.; Qin, R.; Szumlanski, C.L.; Zhao, X.; Dietz, A.B., Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. The Prostate, 2010, 70(4), 443-455.
26. Liu, C.Y.; Wang, Y.M.; Wang, C.L.; Feng, P.H.; Ko, H.W.; Liu, Y.H.; Wu, Y.C.; Chu, Y.; Chung, F.T.; Kuo, C.H.; Lee, K.Y.; Lin, S.M.; Lin, H.C.; Wang, C.H.; Yu, C.T.; Kuo, H.P., Population alterations of L-arginase-and inducible nitric oxide synthaseexpressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol, 2010, 136(1), 35-45.
27. Poschke, I.; Mougiakakos, D.; Hansson, J.; Masucci, G.V.; Kiessling, R., Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res, 2010, 70(11), 4335-4345.
28. Brimnes, M.K.; Vangsted, A.J.; Knudsen, L.M.; Gimsing, P.; Gang, A.O.; Johnsen, H.E.; Svane, I.M., Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol, 2010, 72(6), 540-547.
29. Zea, A.H.; Rodriguez, P.C.; Atkins, M.B.; Hernandez, C.; Signoretti, S.; Zabaleta, J.; McDermott, D.; Quiceno, D.; Youmans, A.; O'Neill, A.; Mier, J.; Ochoa, A.C., Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res, 2005, 65(8), 3044-3048.
30. Rodriguez, P.C.; Ernstoff, M.S.; Hernandez, C.; Atkins, M.; Zabaleta, J.; Sierra, R.; Ochoa, A.C., Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res, 2009, 69(4), 1553-1560.
31. Filipazzi, P.; Valenti, R.; Huber, V.; Pilla, L.; Canese, P.; Iero, M.; Castelli, C.; Mariani, L.; Parmiani, G.; Rivoltini, L., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, 25(18), 2546-2553.
32. Xiang, X.; Poliakov, A.; Liu, C.; Liu, Y.; Deng, Z.B.; Wang, J.; Cheng, Z.; Shah, S.V.; Wang, G.J.; Zhang, L.; Grizzle, W.E.; Mobley, J.; Zhang, H.G., Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer, 2009, 124(11), 2621-2633.
33. Kusmartsev, S.; Su, Z.; Heiser, A.; Dannull, J.; Eruslanov, E.; Kubler, H.; Yancey, D.; Dahm, P.; Vieweg, J., Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, 14(24), 8270-8278.
34. Mandruzzato, S.; Solito, S.; Falisi, E.; Francescato, S.; Chiarion-Sileni, V.; Mocellin, S.; Zanon, A.; Rossi, C.R.; Nitti, D.; Bronte, V.; Zanovello, P., IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol, 2009, 182(10), 6562-6568.
35. Luyckx, A.; Schouppe, E.; Rutgeerts, O.; Lenaerts, C.; Fevery, S.; Devos, T.; Dierickx, D.; Waer, M.; Van Ginderachter, J.A.; Billiau, A.D., G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. Clin Immunol, 2012.
36. Zhao, F.; Hoechst, B.; Duffy, A.; Gamrekelashvili, J.; Fioravanti, S.; Manns, M.P.; Greten, T.F.; Korangy, F., S100A9 a new marker for monocytic human myeloid derived suppressor cells. Immunology, 2012.
37. Lutz, M.B.; Suri, R.M.; Niimi, M.; Ogilvie, A.L.; Kukutsch, N.A.; Rossner, S.; Schuler, G.; Austyn, J.M., Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol, 2000, 30(7), 1813-1822.
38. Abdalla, A.O.; Kiaii, S.; Hansson, L.; Rossmann, E.D.; Jeddi-Tehrani, M.; Shokri, F.; Osterborg, A.; Mellstedt, H.; Rabbani, H., Kinetics of cytokine gene expression in human CD4+ and CD8+ Tlymphocyte subsets using quantitative real-time PCR. Scand J Immunol, 2003, 58(6), 601-606.
39. de Saint-Vis, B.; Fugier-Vivier, I.; Massacrier, C.; Gaillard, C.; Vanbervliet, B.; Ait-Yahia, S.; Banchereau, J.; Liu, Y.J.; Lebecque, S.; Caux, C., The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol, 1998, 160(4), 1666-1676.
40. Morris, M.A.; Ley, K., Trafficking of natural killer cells. Curr Mol Med, 2004, 4(4), 431-438.
41. Croker, B.A.; Metcalf, D.; Robb, L.; Wei, W.; Mifsud, S.; DiRago, L.; Cluse, L.A.; Sutherland, K.D.; Hartley, L.; Williams, E.; Zhang, J.G.; Hilton, D.J.; Nicola, N.A.; Alexander, W.S.; Roberts, A.W., SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity, 2004, 20(2), 153-165.
42. Menetrier-Caux, C.; Montmain, G.; Dieu, M.C.; Bain, C.; Favrot, M.C.; Caux, C.; Blay, J.Y., Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 1998, 92(12), 4778-4791.
43. Pan, P.Y.; Wang, G.X.; Yin, B.; Ozao, J.; Ku, T.; Divino, C.M.; Chen, S.H., Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood, 2008, 111(1), 219-228.
44. Nakamura, Y.; Yasuoka, H.; Tsujimoto, M.; Yoshidome, K.; Nakahara, M.; Nakao, K.; Nakamura, M.; Kakudo, K., Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, 12(4), 1201-1207.
45. Kataru, R.P.; Jung, K.; Jang, C.; Yang, H.; Schwendener, R.A.; Baik, J.E.; Han, S.H.; Alitalo, K.; Koh, G.Y., Critical role of CD11b+ macrophages and VEGF in inflammatory lymphan giogenesis, antigen clearance, and inflammation resolution. Blood, 2009, 113(22), 5650-5659.
46. Nam, E.H.; Park, S.R.; Kim, P.H., TGF-beta1 induces mouse dendritic cells to express VEGF and its receptor (Flt-1) under hypoxic conditions. Experimental & molecular medicine, 2010, 42(9), 606-613.
47. Marek, N.; Mysliwiec, M.; Raczynska, K.; Zorena, K.; Mysliwska, J.; Trzonkowski, P., Increased spontaneous production of VEGF by CD4+ T cells in type 1 diabetes. Clin Immunol, 2010, 137(2), 261-270.
48. Rudnicki, M.; Perco, P.; Enrich, J.; Eder, S.; Heininger, D.; Bernthaler, A.; Wiesinger, M.; Sarkozi, R.; Noppert, S.J.; Schramek, H.; Mayer, B.; Oberbauer, R.; Mayer, G., Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Laboratory investigation; a journal of technical methods and pathology, 2009, 89(3), 337-346.
49. Gabrilovich, D.; Ishida, T.; Oyama, T.; Ran, S.; Kravtsov, V.; Nadaf, S.; Carbone, D.P., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 1998, 92(11), 4150-4166.
50. Gabrilovich, D.I.; Chen, H.L.; Girgis, K.R.; Cunningham, H.T.; Meny, G.M.; Nadaf, S.; Kavanaugh, D.; Carbone, D.P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 1996, 2(10), 1096-1103.
51. Roland, C.L.; Lynn, K.D.; Toombs, J.E.; Dineen, S.P.; Udugamasooriya, D.G.; Brekken, R.A., Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One, 2009, 4(11), e7669.
52. Nefedova, Y.; Nagaraj, S.; Rosenbauer, A.; Muro-Cacho, C.; Sebti, S.M.; Gabrilovich, D.I., Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologicselective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res, 2005, 65(20), 9525-9535.
53. Nefedova, Y.; Huang, M.; Kusmartsev, S.; Bhattacharya, R.; Cheng, P.; Salup, R.; Jove, R.; Gabrilovich, D., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol, 2004, 172(1), 464-474.
54. Kortylewski, M.; Kujawski, M.; Wang, T.; Wei, S.; Zhang, S.; Pilon-Thomas, S.; Niu, G.; Kay, H.; Mule, J.; Kerr, W.G.; Jove, R.; Pardoll, D.; Yu, H., Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med, 2005, 11(12), 1314-1321.
55. Sinha, P.; Clements, V.K.; Fulton, A.M.; Ostrand-Rosenberg, S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res, 2007, 67(9), 4507-4513.
56. Song, X.; Krelin, Y.; Dvorkin, T.; Bjorkdahl, O.; Segal, S.; Dinarello, C.A.; Voronov, E.; Apte, R.N., CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol, 2005, 175(12), 8200-8208.
57. Sauer, H.; Wartenberg, M.; Hescheler, J., Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2001, 11(4), 173-186.
58. Yang, R.; Cai, Z.; Zhang, Y.; Yutzy, W.H.t.; Roby, K.F.; Roden, R.B., CD80 in immune suppression by mouse ovarian carcinomaassociated Gr-1+CD11b+ myeloid cells. Cancer Res, 2006, 66(13), 6807-6815.
59. Ochoa, A.C.; Zea, A.H.; Hernandez, C.; Rodriguez, P.C., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, 13(2 Pt 2), 721s-726s.
60. Bingisser, R.M.; Tilbrook, P.A.; Holt, P.G.; Kees, U.R., Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol, 1998, 160(12), 5729-5734.
61. Rodriguez, P.C.; Zea, A.H.; Culotta, K.S.; Zabaleta, J.; Ochoa, J.B.; Ochoa, A.C., Regulation of T cell receptor CD3zeta chain expression by L-arginine. The Journal of biological chemistry, 2002, 277(24), 21123-21129.
62. Harari, O.; Liao, J.K., Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des, 2004, 10(8), 893-898.
63. Malmberg, K.J.; Arulampalam, V.; Ichihara, F.; Petersson, M.; Seki, K.; Andersson, T.; Lenkei, R.; Masucci, G.; Pettersson, S.; Kiessling, R., Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol, 2001, 167(5), 2595-2601.
64. Mazzoni, A.; Bronte, V.; Visintin, A.; Spitzer, J.H.; Apolloni, E.; Serafini, P.; Zanovello, P.; Segal, D.M., Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol, 2002, 168(2), 689-695.
65. Pacher, P.; Beckman, J.S.; Liaudet, L., Nitric oxide and peroxynitrite in health and disease. Physiological reviews, 2007, 87(1), 315-424.
66. Maeda, H.; Akaike, T., Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry. Biokhimiia, 1998, 63(7), 854-865.
67. Nagaraj, S.; Youn, J.I.; Weber, H.; Iclozan, C.; Lu, L.; Cotter, M.J.; Meyer, C.; Becerra, C.R.; Fishman, M.; Antonia, S.; Sporn, M.B.; Liby, K.T.; Rawal, B.; Lee, J.H.; Gabrilovich, D.I., Antiinflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, 16(6), 1812-1823.
68. Nagaraj, S.; Gupta, K.; Pisarev, V.; Kinarsky, L.; Sherman, S.; Kang, L.; Herber, D.L.; Schneck, J.; Gabrilovich, D.I., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med, 2007, 13(7), 828-835.
69. Roth, J.; Goebeler, M.; Sorg, C., S100A8 and S100A9 in inflammatory diseases. Lancet, 2001, 357(9261), 1041.
70. Tirkos, S.; Newbigging, S.; Nguyen, V.; Keet, M.; Ackerley, C.; Kent, G.; Rozmahel, R.F., Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. Respiratory research, 2006, 7, 51.
71. Nukui, T.; Ehama, R.; Sakaguchi, M.; Sonegawa, H.; Katagiri, C.; Hibino, T.; Huh, N.H., S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. Journal of cellular biochemistry, 2008, 104(2), 453-464.
72. Leach, S.T.; Yang, Z.; Messina, I.; Song, C.; Geczy, C.L.; Cunningham, A.M.; Day, A.S., Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scandinavian journal of gastroenterology, 2007, 42(11), 1321-1331.
73. Bogumil, T.; Rieckmann, P.; Kubuschok, B.; Felgenhauer, K.; Bruck, W., Serum levels of macrophage-derived protein MRP-8/14 are elevated in active multiple sclerosis. Neuroscience letters, 1998, 247(2-3), 195-197.
74. Cheng, P.; Corzo, C.A.; Luetteke, N.; Yu, B.; Nagaraj, S.; Bui, M.M.; Ortiz, M.; Nacken, W.; Sorg, C.; Vogl, T.; Roth, J.; Gabrilovich, D.I., Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med, 2008, 205(10), 2235-2249.
75. Sinha, P.; Okoro, C.; Foell, D.; Freeze, H.H.; Ostrand-Rosenberg, S.; Srikrishna, G., Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol, 2008, 181(7), 4666-4675.
76. Sinha, P.; Clements, V.K.; Ostrand-Rosenberg, S., Interleukin-13- regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res, 2005, 65(24), 11743-11751.
77. Buessow, S.C.; Paul, R.D.; Lopez, D.M., Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. Journal of the National Cancer Institute, 1984, 73(1), 249-255.
78. Greten, T.F.; Manns, M.P.; Korangy, F., Myeloid derived suppressor cells in human diseases. International immunopharma cology, 2011, 11(7), 802-807.
79. Lees, J.R.; Azimzadeh, A.M.; Bromberg, J.S., Myeloid derived suppressor cells in transplantation. Curr Opin Immunol, 2011, 23(5), 692-697.
80. Ueha, S.; Shand, F.H.; Matsushima, K., Myeloid cell population dynamics in healthy and tumor-bearing mice. International immunopharmacology, 2011, 11(7), 783-788.
81. Sawanobori, Y.; Ueha, S.; Kurachi, M.; Shimaoka, T.; Talmadge, J.E.; Abe, J.; Shono, Y.; Kitabatake, M.; Kakimi, K.; Mukaida, N.; Matsushima, K., Chemokine-mediated rapid turnover of myeloidderived suppressor cells in tumor-bearing mice. Blood, 2008, 111(12), 5457-5466.
82. Raychaudhuri, B.; Rayman, P.; Ireland, J.; Ko, J.; Rini, B.; Borden, E.C.; Garcia, J.; Vogelbaum, M.A.; Finke, J., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-oncology, 2011, 13(6), 591-599.
83. Srivastava, M.K.; Zhu, L.; Harris-White, M.; Kar, U.K.; Huang, M.; Johnson, M.F.; Lee, J.M.; Elashoff, D.; Strieter, R.; Dubinett, S.; Sharma, S., Correction: Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer. PLoS One, 2012, 7(10).
84. De Wilde, V.; Van Rompaey, N.; Hill, M.; Lebrun, J.F.; Lemaitre, P.; Lhomme, F.; Kubjak, C.; Vokaer, B.; Oldenhove, G.; Charbonnier, L.M.; Cuturi, M.C.; Goldman, M.; Le Moine, A., Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2009, 9(9), 2034-2047.
85. Cuervo, H.; Guerrero, N.A.; Carbajosa, S.; Beschin, A.; De Baetselier, P.; Girones, N.; Fresno, M., Myeloid-derived suppressor cells infiltrate the heart in acute Trypanosoma cruzi infection. J Immunol, 2011, 187(5), 2656-2665.
86. Tacke, R.S.; Lee, H.C.; Goh, C.; Courtney, J.; Polyak, S.J.; Rosen, H.R.; Hahn, Y.S., Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology, 2012, 55(2), 10.
87. Yin, B.; Ma, G.; Yen, C.Y.; Zhou, Z.; Wang, G.X.; Divino, C.M.; Casares, S.; Chen, S.H.; Yang, W.C.; Pan, P.Y., Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol, 2010, 185(10), 5828-5834.
88. Chou, H.S.; Hsieh, C.C.; Charles, R.; Wang, L.; Wagner, T.; Fung, J.J.; Qian, S.; Lu, L.L., Myeloid-derived suppressor cells protect islet transplants by b7-h1 mediated enhancement of T regulatory cells. Transplantation, 2012, 93(3), 272-282.
89. Zhang, W.; Liang, S.; Wu, J.; Horuzsko, A., Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation, 2008, 86(8), 1125-1134.
90. Shen, L.; Jin, Y.; Freeman, G.J.; Sharpe, A.H.; Dana, M.R., The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol, 2007, 179(6), 3672-3679.